

TABLE OF CONTENTS

RATIFICATION PAGE	ii
ASSERTION	iii
ACKNOWLEDGEMENT.....	iv
TABLE OF CONTENTS	v
LIST OF TABLES	vii
ABSTRACT.....	ix
CHAPTER I	11
1.1 Study Background.....	11
1.2 Problem Formulation	13
1.3 Objectives of Study	13
1.4 Study Authenticity	13
1.5 Study Benefits	14
1.5.1 Benefits for researcher	14
1.5.2 Benefits for health practitioner	14
1.5.3 Benefits for patient.....	14
CHAPTER II.....	15
2.1 Literature Review.....	15
2.1.1 Epidemiology of Hepatitis B	15
2.1.2 Etiopathophysiology of Hepatitis B	16
2.1.3 Natural History of Hepatitis B	18
2.1.4 Age and Gender in Hepatitis B	19
2.1.5 Treatments for Hepatitis B	20
2.1.6 Clinical Progression of Fibrosis and Assessments.....	22
2.2 Theoretical Framework	28
2.3 Conceptual Framework	29
2.4 Hypothesis.....	29
CHAPTER III	30

3.1 Study Design	30
3.1.1 Type of Study Design	30
3.1.2 Place and Time of Study	30
3.2 Population and Sampling	30
3.2.1 Target Population	30
3.2.2 Reachable Population	30
3.2.3 Study Subjects	30
3.2.4 Inclusion Criteria	31
3.2.5 Exclusion Criteria	31
3.3 Sample Size	31
3.4 Study Variables	32
3.5 Operational Definitions	33
3.6 Statistical Analysis	34
3.7 Ethical Consideration	34
CHAPTER IV	35
4.1 Results	35
4.1.1 Characteristics of Research Subject	35
4.1.2 Normality Test	38
4.1.3 Correlation Analysis of PALBI Score with Transient Elastography	38
4.1.4 Correlation Analysis of PALBI Score with Fibrosis Grade	39
4.1. Subanalysis: Fibrosis Grade Groups (Mild and Advanced Fibrosis)	39
4.2 Discussion	39
4.3 Research Limitation	41
CHAPTER V	43
5.1 Conclusions	43
5.2 Suggestions	43
REFERENCES	44

LIST OF TABLES

Table 1. Study Authenticity	13
Table 2. FibroScan Interpretation for Hepatitis B Infection	23
Table 3. Study Variables	32
Table 4. Operational Definition	33
Table 5. Baseline Characteristics of Patients	37
Table 6. Normality Test of Continuous Variables	38
Table 7. Correlation Analysis of PALBI Score with Transient Elastography Result	38
Table 9. Correlation Analysis of PALBI Score with Fibrosis Grade Result	39
Table 10. PALBI Score Difference Based on Fibrosis Grade Groups	39

LIST OF FIGURES

Figure 1. Hepatitis B Virus Infection Phase	18
Figure 2. Bimodal Age Distribution of anti-HBs Prevalence	20